| アブストラクト | BACKGROUND: Previous work has highlighted that migraine is underdiagnosed and undertreated in primary care. AIM: To characterise diagnosis and treatment patterns among patients with migraine in England. DESIGN & SETTING: A retrospective cohort study using the Clinical Practice Research Datalink (CPRD) Aurum linked to the 2019 Index of Multiple Deprivation dataset. METHOD: The study cohort included patients presenting to general practices with migraine at age >/=18 years from September 2012 to May 2023 (index event). Prescribed medications 12 months after index were compared across sociodemographic stratifications (age, sex, ethnic group, and deprivation). Medication overprescription was defined as >/=10 days' (opioids and triptans) or >/=15 days' (analgesics, antipyretics, and non-steroidal anti-inflammatory drugs [NSAIDs]) supply in 3 consecutive months. RESULTS: In total, 1 534 807 patients with any headache or migraine were observed attending primary care in England. Of these, 876 233 (57.1%) were coded with undifferentiated or unclassified headache and 606 928 (39.5%) with a primary headache disorder. Migraine was the most coded primary headache disorder, with 476 191 adults (78.5%), constituting the final sample used for subsequent analyses. Only 36.5% of the migraine cohort were prescribed preventive medication. Regarding prescribed dose, 17.9% of those prescribed amitriptyline, 31.3% prescribed propranolol, and 31.2% prescribed topiramate reached Scottish Intercollegiate Guidelines Network (SIGN) 155 and National Institute for Health and Care Excellence (NICE) Clinical Knowledge Summaries (CKS) recommended doses. In total, 62.6% of the migraine cohort were prescribed an acute medication: triptan (36.6%), and opioid (9.6%). Regarding possible medication overuse, 23.6% of triptan users and 44.3% of opioid users exhibited medication overprescription, as defined by the International Classification of Headache Disorders, 3rd edition (ICHD-3). CONCLUSION: The majority of headache presenting to primary care remains undifferentiated or unclassified. Only approximately one-third of patients diagnosed with migraine receive triptans or preventive medication. Acute medication overprescription is common and preventive medicines are poorly optimised. |
|---|
| ジャーナル名 | BJGP open |
|---|
| Pubmed追加日 | 2026/1/10 |
|---|
| 投稿者 | Watson, David Pb; Pawinski, Robert; Czachorowski, Maciej; Araghi, Marzieh; Williams, Alannah M; Randall, Rowena; Camidge, Lucinda; Rottier, Elke; Gowman, Hannah; Law, Sarah; O'Neil, Grant |
|---|
| 組織名 | Aberdeen Royal Infirmary, Aberdeen, UK.;Medical Affairs, Pfizer Ltd, Tadworth, UK.;Real World Evidence, Adelphi Real World, Bollington, UK.;Medical Affairs, Pfizer Ltd, Tadworth, UK grant.oneil@pfizer.com. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41513289/ |
|---|
